Home
Loading

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

Get in touch

  • Contact

  • Request a demo

  • Request data updates

  • Add a company

Research

  • Companies

  • Investors

  • People

aVenture

  • Sitemap

  • Feature requests

Member

Backed by

© aVenture Investment Company, 2026. All rights reserved.

San Francisco, CA, USA

Privacy Policy

aVenture Investment Company ("aVenture") is an independent research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals. It is not a registered investment adviser, broker-dealer, or investment advisor and does not provide investment advice or recommendations. The data provided by aVenture does not constitute recommendations or advice, whether by methodology, analysis, AI-generated content, or a statement written by a staff member of aVenture.

aVenture is not affiliated with any of the people, companies, organizations, government agencies, regulatory bodies, or investment funds we provide coverage for on this site unless explicitly stated otherwise. Users assume full responsibility for decisions made based on information obtained from this platform. Links to external websites do not imply endorsement or affiliation with aVenture. Any links that provide the ability to invest in a primary or secondary transaction in a company are for convenience only and do not constitute solicitations or offers to buy or sell an investment. Investors should exercise heightened precaution and due diligence when investing in private companies, especially those not independently audited.

While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision. To the fullest extent permitted by law, aVenture shall not be liable for any direct, indirect, incidental, consequential, or financial damages arising from use of this site, whether by consumers of its contents directly or by persons or organizations covered by our research, even if we are advised of the possibility. Our best-efforts processes and correction request forms do not create a warranty or duty of care.

Profiles on this platform may include content generated in part by large language models (LLMs, artificial intelligence) that aggregate publicly available sources (e.g., SEC EDGAR, public filings, press releases). Source attribution is provided where known; always verify statements and claims here against original sources before relying on any data. Content on our site may contain inaccuracies, omissions, or what are commonly called 'hallucinations' if generated in part or in full by AI / LLMs. The risk can also exist even when content is written by a human, as internal and third-party sources may also have inaccuracies for the same or different reasons. While we randomly audit a proportion of content, this is not exhaustive.

We recommend that an independent auditor be hired to verify the accuracy of the information before relying on it for any sensitive decisions. By accessing this platform, you agree not to rely solely on any information generated by AI, aggregated, or sourced or written otherwise on this site, for investment, financial, or other decisions. aVenture assumes no responsibility for inaccuracies, omissions, or hallucinations. You must independently verify all data from primary sources. Use of this platform constitutes your waiver of claims for reliance-based damages, including negligent misrepresentation. To report an error, request a correction, or dispute information about a company or individual, contact us via our request data updates form.

Loading homepage
Loading
Loading
Loading
Home›
Research›
Investment Firms›
Hatteras Venture Partners
AddedFeb 13, 2024
UpdatedJun 28, 2026
Hatteras Venture Partners

Hatteras Venture Partners

Operating

Hatteras Venture Partners: A US-based venture capital firm investing in healthcare and biopharmaceutical sectors.

Location
Durham, NC, US
Founded
2000
Firm
Compare
Portfolio
Employees
Website

Investments

Ladder Health
Ladder Health
Seed

Total Raised

$7M

Rounds

1

Seed$7MJune 2026
Veralox Therapeutics
Veralox Therapeutics

Total Raised

$47.5M

Rounds

4

Series Unknown$24MJune 2023
Series A$16.6MJune 2021
410 Medical
410 Medical

Total Raised

$38.2M

Rounds

12

Series B$7.5MMay 2023
Series B$6.3MNovember 2022
Ten63 Therapeutics
Ten63 Therapeutics

Total Raised

$15.9M

Rounds

3

Series A$15.9MMay 2023
Aer Therapeutics
Aer Therapeutics

Total Raised

$36M

Rounds

1

Series A$36MApril 2023
Mercy BioAnalytics
Mercy BioAnalytics

Total Raised

$68.3M

Rounds

2

Series A$41MApril 2023
Boomerang Medical
Boomerang Medical

Total Raised

$18M

Rounds

2

Series A$15MNovember 2022
Rapidpulse
Rapidpulse

Total Raised

$25.6M

Rounds

2

Series A$10.6MAugust 2022
Series A$15MJune 2021
Code Biotherapeutics
Code Biotherapeutics

Total Raised

$85M

Rounds

2

Series A$75MJune 2022
Wildflower Health
Wildflower Health

Total Raised

$40.8M

Rounds

5

Series Unknown$26MMarch 2022
Huma.AI
Huma.AI

Total Raised

$11.9M

Rounds

4

Series A$9.5MFebruary 2022
Tune Therapeutics
Tune Therapeutics

Total Raised

$40M

Rounds

1

Series A$40MDecember 2021
Trefoil Therapeutics
Trefoil Therapeutics
Series A

Total Raised

$85.8M

Rounds

7

Series A$28MDecember 2021
GeneCentric Therapeutics
GeneCentric Therapeutics

Total Raised

$41.1M

Rounds

6

Series B$7.5MNovember 2021
GoCheck
GoCheck

Total Raised

$22.8M

Rounds

4

Series Unknown$10MOctober 2021
Elligo Health Research
Elligo Health Research

Total Raised

$196M

Rounds

6

Series E$135MSeptember 2021
Boston Immune Technologies & Therapeutics
Boston Immune Technologies & Therapeutics

Total Raised

$10M

Rounds

2

Series A$10MMarch 2021
StrideBio
StrideBio

Total Raised

$97.2M

Rounds

3

Series B$81.5MMarch 2021
Artizan Biosciences
Artizan Biosciences

Total Raised

$33.9M

Rounds

4

Series A$18.9MMarch 2021
Atsena Therapeutics
Atsena Therapeutics

Total Raised

$87.6M

Rounds

3

Series A$55MDecember 2020
Altis Biosystems
Altis Biosystems

Total Raised

$4.5M

Rounds

7

Seed$3.1MJuly 2020
Cvrx
Cvrx
Public

Total Raised

$390.6M

Rounds

10

Private Equity$50MJuly 2020